Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 9, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Leland Gershell Maintained (VRDN) at Buy with Decreased Target to $31 on, May 9th, 2024
Leland Gershell of Oppenheimer, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Decreased Target from $36 to $31 on, May 9th, 2024.
Leland has made no other calls on VRDN in the last 4 months.
There is 1 other peer that has a rating on VRDN. Out of the 1 peers that are also analyzing VRDN, 0 agree with Leland's Rating of Hold.
This is the rating of the analyst that currently disagrees with Leland
- Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $40 on, Wednesday, February 28th, 2024
